NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

de Kruijf, Esther M; Sajet, Anita; van Nes, Johanna GH; Putter, Hein; Smit, Vincent THBM; Eagle, Robert A; Jafferji, Insiya; Trowsdale, John; Liefers, Gerrit Jan; van de Velde, Cornelis JH; Kuppen, Peter JK

doi:10.1186/1471-2407-12-24

Table 2 Correlations between ULBP-3, ULBP-4 and ULBP-5 expression and well-established prognostic factors.

From: NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

	Total		ULBP3				ULBP4						ULBP5
			Low		High		Low		High		Low		High
	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Age
< 40 40-50 50-60 > = 60	48 145 132 249	8.4 25.3 23.0 43.4	25 84 68 128	8.2 27.5 22.3 42.0	11 24 22 55	9.8 21.4 19.6 49.1	29 91 86 164	7.8 24.6 23.2 44.3	15 33 30 49	11.8 26.0 23.6 38.6	38 119 103 185	8.5 26.7 23.1 41.6	3 9 12 23	6.4 19.1 25.5 48.9
Grade
I II III	80 282 203	14.2 49.9 35.9	45 160 96	15.0 53.2 31.9	10 43 57	9.1 39.1 51.8	51 181 134	13.9 49.5 36.6	13 67 43	10.6 54.5 35.0	62 219 157	14.2 50.0 35.8	2 21 23	4.3 45.7 50.0
Histological type
Ductal Lobular	513 53	90.6 9.4	281 20	93.4 6.6	102 8	92.7 7.3	330 37	89.9 10.1	113 10	91.9 8.1	396 43	90.2 9.8	43 3	93.5 6.5
T-status
T1 T2 T3/4	211 272 72	38.0 49.0 13.0	113 142 39	38.4 48.3 13.3	40 54 17	36.0 48.6 15.3	118 180 60	33.0 50.3 16.8	57 61 6	46.0 49.2 4.8	159 209 64	36.8 48.4 14.8	19 26 2	40.4 55.3 4.3
N-status
N0 N1-3	307 250	55.1 44.9	158 135	53.9 46.1	61 49	55.5 44.5	193 170	53.2 46.8	66 55	54.5 45.5	237 196	54.7 45.3	24 21	53.3 46.7
ER-status
Negative Positive	203 337	37.6 62.4	113 178	38.8 61.2	37 73	33.6 66.4	135 222	37.8 62.2	43 80	35.0 65.0	152 278	35.3 64.7	21 25	45.7 54.3
PgR-status
Negative Positive	223 313	41.6 58.4	130 159	45.0 55.0	42 68	38.2 61.8	141 215	39.6 60.4	51 72	41.5 58.5	158 267	37.2 62.8	26 21	55.3 44.7
Her2-status
Overexpression - Overexpression +	378 44	80.9 19.1	207 24	89.6 10.4	82 10	89.1 10.9	256 33	88.6 11.4	93 6	93.9 6.1	311 32	90.7 9.3	35 6	85.4 14.6
Local Therapy
MAST-RT MAST+RT BCS-RT BCS+RT	223 108 5 238	38.9 18.8 0.9 41.5	116 56 3 130	38.0 18.4 1.0 42.6	43 24 1 44	38.4 21.4 0.9 39.3	141 86 1 142	38.1 23.2 0.3 38.4	46 14 3 64	36.2 11.0 2.4 50.4	165 94 4 182	37.1 21.1 0.9 40.9	24 3 0 20	51.1 6.4 0.0 42.6
Systemic therapy
CT alone HT alone CT&HT None	112 75 18 369	19.5 13.1 3.1 64.3	65 32 10 198	21.3 10.5 3.3 64.9	23 10 2 77	20.5 8.9 1.8 68.8	81 52 13 224	21.9 14.1 3.5 60.5	20 16 1 90	20.3 12.6 0.8 70.9	93 60 11 281	20.9 13.5 2.5 63.1	8 5 1 33	17.0 10.6 2.1 70.2
Total	574	100	305	100	112	100	370	100	127	100	445	100	47	100

Missing values are not shown.
AbbreviationsN number of patients; % percentage; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS breast conservative surgery; ET endocrine therapy; CT chemotherapy.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us